https://www.selleckchem.com/pr....oducts/s64315-mik665
BACKGROUND Metformin may reduce cancer risk and mortality and improve radiotherapy responses in several malignancies. OBJECTIVE To compare tumor responses and prognoses of metformin and non-metformin groups of diabetic patients receiving neoadjuvant concurrent chemoradiotherapy for rectal cancer. DESIGN Retrospective study. SETTING Single institution in the Republic of Korea. PATIENTS Between January 2000 and November 2017, 104 patients with rectal cancer taking diabetes medication and treated with neoadjuvant concurrent chemoradi
Like
Comment
Share
